Skip to main content
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. — Investor Relations & Filings

Ticker · CADL ISIN · US1374041093 US Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country US United States of America
Listing US CADL

About Candel Therapeutics, Inc.

https://www.candeltx.com/

Candel Therapeutics, Inc. is a company developing viral immunotherapies designed to activate a patient's immune system to fight cancer. Its approach utilizes two main platforms based on engineered adenovirus and Herpes Simplex Virus (HSV). These investigational, off-the-shelf therapies are administered directly into tumors to induce immunogenic cell death. This process is intended to stimulate a personalized, systemic, and durable anti-tumor response specific to the individual's cancer. The company aims to create treatments that are both efficacious and well-tolerated for patients across various disease stages.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-15 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Regulatory Filings
2026-05-14 English
4 - CANDEL THERAPEUTICS, INC. (0001841387) (Filer)
Director's Dealing
2026-02-26 English
8-K - CANDEL THERAPEUTICS, INC. (0001841387) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 19, 2026, by Candel Therapeutics, Inc. It reports the entry into a material definitive agreement, specifically an underwriting agreement for a public offering of common stock. The document details the terms of the offering, the expected proceeds, and the intended use of funds. It also references exhibits including the underwriting agreement and related press releases. The content focuses on a financing transaction and capital raising activity. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The document is not a report publication announcement but the actual filing of a current report on a material event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-02-23 English
8-K - CANDEL THERAPEUTICS, INC. (0001841387) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to a purchase and sale agreement for royalties contingent on FDA approval of a product. It also includes preliminary financial information and a press release. There are no comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy, or governance report. It is a regulatory filing announcing a material event, consistent with the purpose of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (9717 characters) and detailed event description support this classification with high confidence.
2026-02-19 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.